Education is the most powerful weapon which you can use to change the world-Nelson Mandela
Investment Analysis:
The scientific development and approval of Obeticholic acid (OCA; Ocaliva) therapy developed by Intercept (ICPT) Pharmaceuticals for Primary Biliary Cholangitis ((PBC)) in 2016 was a remarkable achievement for the scientific community but more importantly for the patients diagnosed with this disease. PBC is a progressive cholestatic liver disease with limited or no therapeutic option. OCA was given a conditional approval based on further evaluation in ongoing Phase 4 COBALT trial to determine if clinical benefits